Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2002;8(15):1375-89.
doi: 10.2174/1381612023394539.

Duocarmycins--natures Prodrugs?

Affiliations
Review

Duocarmycins--natures Prodrugs?

Mark Searcey. Curr Pharm Des. .

Abstract

The duocarmycins and (+)-CC-1065 are amongst the most potent antitumour antibiotics discovered to date and yet have not progressed into the clinic. The natural products are extremely stable to nucleophilic attack until bound to their DNA target and are not substrates for any other biological nucleophile. The mechanism for this target activation of the duocarmycins is discussed with relation to both an acid-catalyzed activation and a binding-induced conformational change leading to ground state destabilization. It is suggested that targeting of the duocarmycins to their site of action in a tumour may be more important than introducing systemically-activated prodrugs as the natural product itself can be considered to be a type of prodrug, activated only on binding to its targets. Methods that have been used to target CC-1065 and the duocarmycins are reviewed as well as efforts towards systemically activated prodrugs. A simple analysis of the approaches that could be taken to vary the structure for targeting is suggested.

Similar articles

See all similar articles

Cited by 11 articles

See all "Cited by" articles

Publication types

MeSH terms

LinkOut - more resources

Feedback